EMA Recommends Granting a Marketing Authorisation for Poherdy By Ogkologos - April 10, 2026 199 0 Facebook Twitter Google+ Pinterest WhatsApp It is a biosimilar of pertuzumab which was authorised in the EU in 2013 Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cómo mi diagnóstico de cáncer a los 17 años cambió mi... December 14, 2020 Do Birth Control Pills Impact My Cancer Risk? October 20, 2022 New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... May 20, 2021 The Nobel Prize winner helping us treat children’s cancers November 8, 2022 Load more HOT NEWS Identifying Safer Ways to Look for Recurrence After Testicular Cancer Surgery A Rare Childbirth Complication Wiped This Woman’s Memory Of Giving Birth... Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO... Unravelling the mystery of Barrett’s oesophagus
